MF59
Phase 2Biologic
NovartisMF59 is one of 25 biologic programs targeting Influenza. It is currently in Phase 2.
2
Indications
16
Total Trials
2
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Crestor
AstraZenecaPreclinical
MF59
NovartisPhase 2
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
PD-1/PD-L1 Inhibitors
CChuangzhen Chen
Preclinical
Fluvirin
NovartisPreclinical
Flulaval
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Influenza4 trials
Immunogenicity2 trials
A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000832·30 enrolled
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001042·112 enrolled
Adult2 trials
H7N9 Mix and Match With AS03 and MF59 in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01942265·980 enrolled
H7N9 Mix and Match With MF59 in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01938742·700 enrolled
Antibody Response1 trial
Elderly Person1 trial
H7N9 Mix and Match With MF59 in Healthy Elderly Persons
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02213354·479 enrolled
6 more indications
HIV-11 trial
Avian Influenza1 trial
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03682120·372 enrolled
Pregnant Women1 trial
Effectiveness1 trial
Immunology1 trial
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03014310·388 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MF59. EMBL-EBI & Wellcome Sanger Institute.
- [4]